First-line combination chemotherapy with cisplatin, etoposide and ifosfamide for the treatment of disseminated germ cell cancer: re-evaluation in the granulocyte colony-stimulating factor era.

Abstract

BACKGROUND:

This study re-evaluated the efficacy and tolerability of cisplatin, etoposide, and ifosfamide (VIP) combination chemotherapy as an alternative first-line regimen for patients with disseminated germ cell cancer (GCC) in this granulocyte colony-stimulating factor (G-CSF) era.

METHODS:

The medical records of 91 consecutive patients with previously untreated disseminated GCC who received first-line VIP between 1995 and 2011 were retrospectively reviewed.

RESULTS:

The 5-year overall survival rates for patients with good (n = 49), intermediate (n = 22) and poor (n = 20) prognoses according to the International Germ Cell Cancer Collaborative Group classification were 100, 79 and 83%, respectively. G-CSF was given to all patients, and no treatment-related deaths due to myelosuppression occurred.

CONCLUSION:

The present study is the first to examine the therapeutic outcomes and safety profile of first-line VIP after routine G-CSF use. VIP might be an alternative first-line regimen for patients with disseminated GCC in this G-CSF era.

• Authors: Hajime Tanaka, Takeshi Yuasa, Yasuhisa Fujii, Mizuaki Sakura, Shinji Urakami, Shinya Yamamoto, Hitoshi Masuda, Iwao Fukui, Junji Yonese
• Journal: Chemotherapy (Chemotherapy) Vol. 59 Issue 6 Pg. 441-6 ( 2013) ISSN: 1421-9794 [Electronic] Switzerland
• PMID: 25060582 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2014 S. Karger AG, Basel

Chemical References

• Antineoplastic Agents
• Granulocyte Colony-Stimulating Factor
• Etoposide
• Cisplatin
• Ifosfamide

Topics

• Adult
• Antineoplastic Agents (adverse effects, therapeutic use)
• Cisplatin (adverse effects, therapeutic use)
• Disease-Free Survival
• Drug Therapy, Combination
• Etoposide (adverse effects, therapeutic use)
• Follow-Up Studies
• Granulocyte Colony-Stimulating Factor (therapeutic use)
• Hematologic Diseases (etiology)
• Humans
• Ifosfamide (adverse effects, therapeutic use)
• Male
• Mediastinal Neoplasms (drug therapy)
• Middle Aged
• Neoplasms, Germ Cell and Embryonal (drug therapy)
• Retroperitoneal Neoplasms (drug therapy)
• Retrospective Studies
• Survival Rate
• Testicular Neoplasms (drug therapy)